Pompe disease is a rare genetic disorder that causes severe muscle weakness, heart and respiratory failure, and ends in early death. Patients rely on lifelong enzyme infusions that only slow disease progression, as most of the enzyme fails to reach affected cells and triggers immune reactions. The current market for enzyme therapies in Pompe disease is around $2 billion. We are a team of 3 scientists from the University of Basel with backgrounds in nanotechnology, biochemistry, and clinical immunology, working at the intersection of drug delivery and rare diseases. Our technology aims to improve how enzymes are delivered to cells, making treatments safer and more effective.